Efficacy of Almonertinib Versus Osimertinib as the First‐Line Treatment for Non‐Small Cell Lung Cancer With <scp>EGFR L858R</scp> Mutation and Prognostic Analysis: A Retrospective Comparative Cohort Study
Both almonertinib and osimertinib demonstrated good efficacy in patients with brain metastases, and PD-L1 expression was not associated with the prognosis of EGFR L858R mutant NSCLC. Finally, no significant difference between osimertinib and almonertinib for the treatment of patients with EGFR L858R mutations was observed. Both options remain viable for these patients.
Authors
- Ruyue Li (ORCID: https://orcid.org/0000-0001-9219-5332)
- Yintao Li (ORCID: https://orcid.org/0000-0003-4665-8900)
- Dong Xue (ORCID: https://orcid.org/0000-0002-7969-7386)
- Ying Li (ORCID: https://orcid.org/0000-0002-2693-6056)
- Xiujing Yao (ORCID: https://orcid.org/0009-0006-8420-9814)
Institutions
- Weifang Medical University (CN)
- Shandong Tumor Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1002/cam4.71422
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province